Clutterbuck E, Shields J G, Gordon J, Smith S H, Boyd A, Callard R E, Campbell H D, Young I G, Sanderson C J
National Institute for Medical Research, Mill Hill, London, GB.
Eur J Immunol. 1987 Dec;17(12):1743-50. doi: 10.1002/eji.1830171210.
Following the observation that mouse interleukin 5 (IL5) is active as a B cell growth factor (BCGF) as well as an eosinophil differentiation factor, this work was carried out to test recombinant human IL5 for BCGF activity. A highly active, partially purified batch of recombinant human IL5 was prepared and tested for BCGF activity in four laboratories. This batch gave a 50% endpoint of 1:77,450 in the human eosinophil differentiation assay, 1:983 in the mouse eosinophil differentiation assay and 1:42 in the mouse BCL1 assay, thus demonstrating that, like mouse IL5, human IL5 has cross-species activity. By comparison with the assays in the mouse this batch would be expected to have 50% maximal human BCGF activity of about 1:4000. In each assay a known positive factor was used as a positive control, and there was no inhibitory activity in the preparation. However, despite the activity towards the mouse B cell lymphoma, the results showed no detectable activity in a panel of assays used to identify human BCGF and B cell differentiation factors. These assays included (a) proliferation assays with tonsillar or splenic B cells in the presence of the co-stimulators anti-mu or phorbol myristate acetate; (b) a restimulation assay in which tonsillar B cells are first activated with either Staphylococcus aureus Cowan 1 or a mixture of phorbol dibutyrate and ionomycin, or splenic B cells are first activated with anti-mu; (c) production of immunoglobulin by B cells in a restimulation assay with Staphylococcus aureus Cowan 1; (d) production of immunoglobulin by the Epstein-Barr virus-transformed B lymphoblastoid CESS cell line; (e) the ability to stimulate proliferation of chronic lymphocytic leukemia (B-CLL) cells freshly explanted from three different patients; (f) the ability to stimulate the B lymphoma (L4) cell line and the mature B cell (HBF1) line, and (g) the ability to replace T cells in specific antibody responses. It therefore seems unlikely that recombinant human IL5 is either a growth or a differentiation factor for human B cells, and raises the interesting question of the biological significance of the BCGF activity of this factor in the mouse.
在观察到小鼠白细胞介素5(IL5)作为B细胞生长因子(BCGF)以及嗜酸性粒细胞分化因子具有活性之后,开展了这项工作以测试重组人IL5的BCGF活性。制备了一批高活性、部分纯化的重组人IL5,并在四个实验室测试其BCGF活性。这批重组人IL5在人嗜酸性粒细胞分化试验中的50%终点为1:77,450,在小鼠嗜酸性粒细胞分化试验中为1:983,在小鼠BCL1试验中为1:42,从而表明,与人IL5一样,人IL5具有跨物种活性。与小鼠试验相比,预计这批重组人IL5的最大人BCGF活性的50%约为1:4000。在每个试验中,使用已知的阳性因子作为阳性对照,并且制剂中没有抑制活性。然而,尽管对小鼠B细胞淋巴瘤有活性,但结果显示在用于鉴定人BCGF和B细胞分化因子的一组试验中未检测到活性。这些试验包括:(a)在共刺激剂抗μ或佛波醇肉豆蔻酸酯存在下,用扁桃体或脾B细胞进行的增殖试验;(b)一种再刺激试验,其中扁桃体B细胞首先用金黄色葡萄球菌Cowan 1或佛波醇二丁酸酯和离子霉素的混合物激活,或者脾B细胞首先用抗μ激活;(c)在与金黄色葡萄球菌Cowan 1的再刺激试验中,B细胞产生免疫球蛋白;(d)爱泼斯坦-巴尔病毒转化的B淋巴母细胞样CESS细胞系产生免疫球蛋白;(e)刺激从三名不同患者新分离的慢性淋巴细胞白血病(B-CLL)细胞增殖的能力;(f)刺激B淋巴瘤(L4)细胞系和成熟B细胞(HBF1)系的能力,以及(g)在特异性抗体反应中替代T细胞的能力。因此,重组人IL5似乎不太可能是人B细胞的生长或分化因子,这就提出了该因子在小鼠中的BCGF活性的生物学意义这一有趣问题。